Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ARBITRATION RULING REAFFIRMS ALLOGENE'S FULL CONTROL OF CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) DECISION RECONFIRMS ALLOGENE'S EXPANDED SUB-LICENSE COVERING EU AND UK RIGHTS WITH OPTIONS FOR JAPAN AND CHINA, CLEARING THE PATH FOR ALLOGENE TO ACQUIRE FULL GLOBAL RIGHTS 1H 2026 INTERIM FUTILITY ANALYSIS FROM THE PIVOTAL PHASE 2 ALPHA3 TRIAL WITH CEMA-CEL IN FIRST-LINE (1L) CONSOLIDATION LARGE B-CELL LYMPHOMA (LBCL) REMAINS ON TRACK SOUTH SAN FRANCISCO, CALIF., DEC. 15, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY NOTED THE FAVORABLE OUTCOME FOR SERVIER IN ITS ARBITRATION WITH CELLECTIS (EURONEXT GROWTH: ALCLS  NASDAQ: CLLS) AS IT RELATES TO CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL).

ALLOGENE THERAPEUTICS REPORTS FAVORABLE RESULT FOR SERVIER IN ARBITRATION WITH CELLECTIS

NEW YORK, DEC. 15, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS  NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCES THAT THE ARBITRAL TRIBUNAL HAS ISSUED ITS DECISION IN THE ARBITRATION PROCEEDINGS AGAINST LESLABORATOIRES SERVIERANDINSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS SARL (SERVIER), RELATING TO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT ENTERED INTO BETWEEN SERVIER AND CELLECTIS ON MARCH 6, 2019, AS AMENDED (THE LICENSE AGREEMENT).

CELLECTIS ANNOUNCES ARBITRAL DECISION IN DISPUTE WITH SERVIER

NEW YORK, DEC. 08, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS  NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCED THE PRESENTATION OF ENCOURAGING UPDATED DATA OF PATIENTS TREATED IN THE PHASE 1 NATHALI-01 CLINICAL TRIAL WITH ETI-CEL, AT THE 67TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) IN ORLANDO, FL.

ASH 2025: CELLECTIS PRESENTS DEVELOPMENT PLAN TO FURTHER ENHANCE HIGH RESPONSE RATE OBSERVED FOR ETI-CEL IN R/R NHL

(ARTICLE 223-16 OF GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY) (ARTICLE 223-16 OF GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY)

MONTHLY INFORMATION ON SHARE CAPITAL AND COMPANY VOTING RIGHTS

NEW YORK, NOV. 19, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS  NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY PUBLISHES AN ARTICLE IN NATURE COMMUNICATIONS ESTABLISHING CIRCULAR SINGLE-STRANDED DNA (CSSDNA) AS A HIGHLY EFFICIENT NON-VIRAL DNA DONOR TEMPLATE, FOR GENE INSERTION IN HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS).

CELLECTIS PUBLISHES NATURE COMMUNICATIONS ARTICLE ON A NON-VIRAL GENE EDITING PROCESS ENABLING EFFICIENT GENE INSERTION IN HEMATOPOIETIC STEM CELLS

PRESENTED DATA UNDERSCORE THE POTENTIAL OF LASME-CEL (UCART22) AND ETI-CEL (UCART20X22) TO IMPROVE OUTCOMES IN R/R B-ALL AND R/R NHL: LASME-CEL IN R/R B-ALL (BALLI-01) ORR OF 68% WITH LASME-CEL PROCESS 2 (N=22), 83% AT RP2D (N=12) AND 100% IN THE TARGET PHASE 2 POPULATION (N=9) MEDIAN OS OF 14.8 MONTHS IN PATIENTS WHO ACHIEVED MRD-NEGATIVE CR/CRI FIRST INTERIM ANALYSIS FOR THE BALLI-01 TRIAL EXPECTED IN Q4 2026 ETI-CEL IN R/R NHL (NATHALI-01) ORR OF 86% AND 57% CR RATE (N=7) DEVELOPMENT UPDATE TO BE PRESENTED AT THE ASH 2025 ANNUAL MEETING FULL PHASE 1 DATASET EXPECTED TO BE SHARED IN 2026 SERVIER ARBITRATION: ARBITRAL DECISION EXPECTED TO BE RENDERED ON OR BEFORE DECEMBER 15, 2025 CASH, CASH EQUIVALENTS AND FIXED-TERM DEPOSITS OF $225 MILLION AS OF SEPTEMBER 30, 2025 1 PROVIDES RUNWAY INTO H2 2027 NEW YORK, NOV. 07, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY PROVIDED FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 ENDING SEPTEMBER 30, 2025 AND BUSINESS UPDATES. WE ARE PROUD OF THE PROMISING DATA FROM OUR CORE CLINICAL PRODUCT CANDIDATES.

CELLECTIS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, NOV. 03, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCED TODAY THE ACCEPTANCE OF TWO ABSTRACTS FOR POSTER PRESENTATION AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2025 ANNUAL MEETING TAKING PLACE FROM DECEMBER 6 TO 9, 2025, IN ORLANDO, FL.

CELLECTIS TO PRESENT A DEVELOPMENT UPDATE FOR ETI-CEL AT ASH 2025

NEW YORK, OCT. 31, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 ENDING SEPTEMBER 30, 2025 ON FRIDAY, NOVEMBER 7, 2025 AFTER THE CLOSE OF THE US MARKET.

Cellectis S.A.

CLLS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cellectis S.A.

CLLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CLLS